close

Vertex Pharmaceuticals Incorporated engages in the discovery, development, and commercialization of small molecule drugs for the treatment of serious diseases worldwide. Its product pipeline includes Telaprevir, a Phase III clinical trial product for the treatment of hepatitis C virus (HCV) infection; VX-813, a Phase Ia clinical trial product for chronic HCV infection; VX-985, which is under preclinical trails for chronic HCV infection; VX-770, a Phase IIa clinical trial candidate for the treatment of Cystic fibrosis; VX-809, a Phase Ib clinical trial product for the treatment of Cystic fibrosis; VX-509, a Phase Ia clinical trial product for immune-mediated inflammatory diseases; MK-5108 (VX-689), a Phase I clinical trial product for the treatment of cancer; and AVN-944(VX-944), which is in Phase 2 clinical trial for the treatment of cancer. The company also has development and commercial rights to VX-702 for the treatment of rheumatoid arthritis and other inflammatory diseases. It has collaboration agreements with Janssen Pharmaceutica, N.V.; Mitsubishi Tanabe Pharma Corporation; Cystic Fibrosis Foundation Therapeutics Incorporated; Merck & Co., Inc.; Avalon Pharmaceuticals, Inc.; and GlaxoSmithKline plc. Vertex Pharmaceuticals was founded in 1989 and is headquartered in Cambridge, Massachusetts.

(login to add this stock to your watchlist or favorites)

Key Statistics

Closing Price	41.32
Volume	(mio) 1.74
Volume Avg	(mio) 3.15
52 Week High	58.87
52 Week Low	26.50
PE	298.00
PE (group average)	39
EPS Year	0.14
EPS change Q/Q	-3.33%
EPS change Q/Q Yr ago	-4.82%
EPS change Q/Q next Q est	1000%
EPS change Y/Y	-7.61%
REV change Q/Q	12.52%
REV change Q/Q Yr ago	229.02%
EPS next Q est	0.75
EPS next Y est	3.39
Divident Annual	0.00
Dividend Yield	0%